IL294156A - Treatment of mild traumatic brain injury - Google Patents
Treatment of mild traumatic brain injuryInfo
- Publication number
- IL294156A IL294156A IL294156A IL29415622A IL294156A IL 294156 A IL294156 A IL 294156A IL 294156 A IL294156 A IL 294156A IL 29415622 A IL29415622 A IL 29415622A IL 294156 A IL294156 A IL 294156A
- Authority
- IL
- Israel
- Prior art keywords
- ghrelin
- variant
- days
- mtbi
- symptoms
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 60
- 208000007333 Brain Concussion Diseases 0.000 title claims description 20
- 101800001586 Ghrelin Proteins 0.000 claims description 135
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims description 135
- 208000024891 symptom Diseases 0.000 claims description 98
- 238000000034 method Methods 0.000 claims description 43
- 230000002459 sustained effect Effects 0.000 claims description 33
- 208000014674 injury Diseases 0.000 claims description 30
- 208000027418 Wounds and injury Diseases 0.000 claims description 29
- 230000006378 damage Effects 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 21
- 238000003745 diagnosis Methods 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 230000000116 mitigating effect Effects 0.000 claims description 4
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 102000012004 Ghrelin Human genes 0.000 claims 14
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 121
- 230000006872 improvement Effects 0.000 description 38
- 206010010254 Concussion Diseases 0.000 description 23
- 230000009514 concussion Effects 0.000 description 23
- 238000012360 testing method Methods 0.000 description 22
- 208000008348 Post-Concussion Syndrome Diseases 0.000 description 16
- 230000008859 change Effects 0.000 description 16
- 239000000902 placebo Substances 0.000 description 16
- 229940068196 placebo Drugs 0.000 description 16
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 238000012216 screening Methods 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 10
- 230000001154 acute effect Effects 0.000 description 9
- 208000029028 brain injury Diseases 0.000 description 9
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 8
- 230000001149 cognitive effect Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 230000000007 visual effect Effects 0.000 description 7
- 230000002411 adverse Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000007774 longterm Effects 0.000 description 5
- 238000002483 medication Methods 0.000 description 5
- 230000019771 cognition Effects 0.000 description 4
- 208000010877 cognitive disease Diseases 0.000 description 4
- 230000003920 cognitive function Effects 0.000 description 4
- 230000002996 emotional effect Effects 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 208000000044 Amnesia Diseases 0.000 description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 description 3
- 208000003443 Unconsciousness Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003931 cognitive performance Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000009529 traumatic brain injury Effects 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- 208000003164 Diplopia Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 206010071366 Post-traumatic neck syndrome Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 208000021567 Whiplash injury Diseases 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 229940039856 aricept Drugs 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000006999 cognitive decline Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 208000029444 double vision Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960004640 memantine Drugs 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 229940033872 namenda Drugs 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- -1 semisolids Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000012030 stroop test Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- 206010070246 Executive dysfunction Diseases 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000022214 Post-traumatic amnestic disease Diseases 0.000 description 1
- 208000031074 Reinjury Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007106 neurocognition Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962953130P | 2019-12-23 | 2019-12-23 | |
| PCT/US2020/066703 WO2021133844A1 (en) | 2019-12-23 | 2020-12-22 | Treatment of mild traumatic brain injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL294156A true IL294156A (en) | 2022-08-01 |
Family
ID=76575665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL294156A IL294156A (en) | 2019-12-23 | 2020-12-22 | Treatment of mild traumatic brain injury |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230031262A1 (https=) |
| EP (1) | EP4081238A4 (https=) |
| JP (1) | JP2023508250A (https=) |
| KR (1) | KR20220122691A (https=) |
| CN (1) | CN114980915A (https=) |
| AU (1) | AU2020412765A1 (https=) |
| BR (1) | BR112022012365A2 (https=) |
| CA (1) | CA3165738A1 (https=) |
| IL (1) | IL294156A (https=) |
| MX (1) | MX2022007844A (https=) |
| WO (1) | WO2021133844A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220370804A1 (en) * | 2021-01-22 | 2022-11-24 | The Regents Of The University Of Colorado, A Body Corporate | Motor learning and vagus nerve stimulation (vns) paired with motor learning to treat demyelinating diseases, conditions and disorders |
| CN113723530B (zh) * | 2021-09-02 | 2022-03-25 | 中国科学院自动化研究所 | 基于视频分析和电子心理沙盘的智能心理评估系统 |
| AU2023338304A1 (en) * | 2022-09-07 | 2025-04-10 | Oxeia Biopharmaceuticals, Inc. | Treatment of mild traumatic brain injury |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6545697B2 (ja) * | 2013-11-15 | 2019-07-17 | ニューラル・アナリティクス・インコーポレーテッド | 神経学的状態の診断のための脳の血流速度の構造的特徴をモニタリングすること |
| US9119832B2 (en) * | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| WO2015168103A1 (en) * | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| AU2015305647A1 (en) * | 2014-08-19 | 2017-04-06 | Oxeia Biopharmaceuticals, Inc. | Methods of treating mild brain injury |
| WO2016134215A1 (en) * | 2015-02-19 | 2016-08-25 | The Regents Of The University Of California | Methods of treating mild brain injury and post-traumatic stress disorder |
| US20180071367A1 (en) * | 2015-03-09 | 2018-03-15 | Oxeia Biopharmaceuticals, Inc. | Methods of treating cognitive impairments or dysfunction |
| WO2017075535A1 (en) * | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
-
2020
- 2020-12-22 BR BR112022012365A patent/BR112022012365A2/pt not_active Application Discontinuation
- 2020-12-22 WO PCT/US2020/066703 patent/WO2021133844A1/en not_active Ceased
- 2020-12-22 EP EP20905518.5A patent/EP4081238A4/en active Pending
- 2020-12-22 AU AU2020412765A patent/AU2020412765A1/en active Pending
- 2020-12-22 KR KR1020227025653A patent/KR20220122691A/ko not_active Withdrawn
- 2020-12-22 CA CA3165738A patent/CA3165738A1/en active Pending
- 2020-12-22 IL IL294156A patent/IL294156A/en unknown
- 2020-12-22 JP JP2022564096A patent/JP2023508250A/ja active Pending
- 2020-12-22 CN CN202080092650.7A patent/CN114980915A/zh active Pending
- 2020-12-22 US US17/787,848 patent/US20230031262A1/en active Pending
- 2020-12-22 MX MX2022007844A patent/MX2022007844A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022012365A2 (pt) | 2022-08-30 |
| CN114980915A (zh) | 2022-08-30 |
| CA3165738A1 (en) | 2021-07-01 |
| JP2023508250A (ja) | 2023-03-01 |
| US20230031262A1 (en) | 2023-02-02 |
| AU2020412765A1 (en) | 2022-07-14 |
| WO2021133844A1 (en) | 2021-07-01 |
| EP4081238A4 (en) | 2023-08-30 |
| EP4081238A1 (en) | 2022-11-02 |
| MX2022007844A (es) | 2022-09-07 |
| KR20220122691A (ko) | 2022-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Busse et al. | Liberty Asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma | |
| Decramer et al. | Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials | |
| McGuinness et al. | Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia | |
| Zubcevic et al. | Oral capsules of tetra‐hydro‐cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment | |
| Ingebrigtsen et al. | Characteristics of undertreatment in COPD in the general population | |
| IL294156A (en) | Treatment of mild traumatic brain injury | |
| Rose et al. | Treatment for inclusion body myositis | |
| Dart et al. | The Efficacy of Antivenin Latrodectus (Black Widow) Equine Immune F (abʹ) 2 Versus Placebo in the Treatment of Latrodectism: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial | |
| Kardas et al. | Adherence to treatment in asthma and COPD patients in their doctors’ assessment | |
| Papapetropoulos et al. | A phase 2, randomized, double-blind, placebo-controlled trial of CX-8998, a selective modulator of the T-type calcium channel in inadequately treated moderate to severe essential tremor: T-CALM study design and methodology for efficacy endpoint and digital biomarker selection | |
| Pearlman et al. | Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6–< 12 years) | |
| Zhang et al. | Decoding the impact of the placebo response in clinical trials for chronic cough | |
| Perrin et al. | Randomized controlled trial of adherence with single or combination inhaled corticosteroid/long-acting β-agonist inhaler therapy in asthma | |
| Licari et al. | Critical reappraisal of short-acting bronchodilators for pediatric respiratory diseases | |
| Smith et al. | Safety and efficacy of topiramate in individuals with cryptogenic sensory peripheral neuropathy with metabolic syndrome: the TopCSPN randomized clinical trial | |
| Haikazian et al. | Real world effectiveness of maintenance ketamine infusions for treatment-resistant depression in major depressive disorder and bipolar disorder | |
| Al-Khazali et al. | Hemicrania continua: an update | |
| 七海陽子 et al. | Effectiveness of pharmacists' comprehensive assessment of medication profiles in dementia patients | |
| US20260077018A1 (en) | Treatment of mild traumatic brain injury | |
| Attallah et al. | Efficacy, safety and quality of life of oxybutynin versus aluminum chloride hexahydrate in treating primary palmar hyperhidrosis | |
| Stempel et al. | Comparative efficacy and cost of asthma care in children with asthma treated with fluticasone propionate and montelukast | |
| HK40080092A (en) | Treatment of mild traumatic brain injury | |
| Manti et al. | Efficacy and perceived satisfaction of 3-year SLIT in children with allergic rhinitis and asthma: A pilot study in real-life. | |
| Pérez-Garrigues et al. | Patient baseline characteristics in an open-label multinational study of betahistine in recurrent peripheral vestibular vertigo: the OSVaLD study | |
| Khokhar et al. | Vaccination counseling with and without excipient skin testing in patients with suspected allergic reactions to mRNA COVID-19 vaccines and patients with atopy |